{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:16:42Z","timestamp":1771042602439,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/jac\/dky448","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T19:17:35Z","timestamp":1538767055000},"page":"295-297","source":"Crossref","is-referenced-by-count":23,"title":["Minocycline susceptibility breakpoints for<i>Acinetobacter baumannii<\/i>: do we need to re-evaluate them?"],"prefix":"10.1093","volume":"74","author":[{"given":"Athanasios","family":"Tsakris","sequence":"first","affiliation":[{"name":"Department of Microbiology, Medical School, University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Koumaki","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Medical School, University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristides","family":"Dokoumetzidis","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"key\n\t\t\t\t2019012511212531300_dky448-B1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijantimicag.2009.06.021","article-title":"Minocycline\u2014an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii","volume":"34","author":"Bishburg","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijantimicag.2016.05.017","article-title":"Comparative evaluation of minocycline susceptibility testing methods in carbapenem-resistant Acinetobacter baumannii","volume":"48","author":"Dimitriadis","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B3","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/cid\/ciu706","article-title":"Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options","volume":"59","author":"Castanheira","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B4","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1093\/cid\/ciu613","article-title":"A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections","volume":"59","author":"Ritchie","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B5","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.cmi.2015.07.007","article-title":"Minocycline activity against clinical isolates of multidrug-resistant Acinetobacter baumannii","volume":"21","author":"Adibhesami","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1128\/AAC.01097-08","article-title":"In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group","volume":"53","author":"Arroyo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B7","volume-title":"Performance Standards for Antimicrobial Disc Susceptibility Tests\u2014First Edition: Approved Standard M2-A","author":"National Committee for Clinical Laboratory Standards","year":"1976"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B8","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1128\/JCM.00143-07","article-title":"Reevaluation of Clinical and Laboratory Standards Institute disk diffusion breakpoints for tetracyclines for testing Enterobacteriaceae","volume":"45","author":"Sader","year":"2007","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B9","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17","author":"Clinical and Laboratory Standards Institute","year":"2007"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jac\/49.3.479","article-title":"Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)","volume":"49","author":"Henwood","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B11","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2013"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/cpt1973145852","article-title":"Pharmacokinetic studies on minocycline in man","volume":"14","author":"Macdonald","year":"1973","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B14","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1128\/AAC.00922-07","article-title":"Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model","volume":"52","author":"Bowker","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1469-0691.2006.01617.x","article-title":"The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis","volume":"13","author":"Burgess","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B16","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1128\/JCM.00125-13","article-title":"Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae","volume":"51","author":"Dallas","year":"2013","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ijantimicag.2017.06.026","article-title":"Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection","volume":"50","author":"Alfouzan","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF01969570","article-title":"One-dose and multiple-dose kinetics of minocycline in patients with renal disease","volume":"7","author":"Sklenar","year":"1977","journal-title":"Agents Actions"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B19","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/aws072","article-title":"Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury","volume":"135","author":"Casha","year":"2012","journal-title":"Brain"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B20","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/jac\/dkx039","article-title":"The complexity of minocycline serum protein binding","volume":"72","author":"Zhou","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019012511212531300_dky448-B21","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2015"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/2\/295\/27524632\/dky448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T14:35:04Z","timestamp":1572014104000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/2\/295\/5166734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,11,8]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky448","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,11,8]]}}}